Weam Aldiban: The Critical Impact of Pharmacogenetic Variation on Dabigatran Exposure and Bleeding Risk
Weam Aldiban, Head of Pharmacology & Toxicology Department at IUST University, shared a post on LinkedIn:
“Excited to share our latest publication in Human Genomics!
Title: The role of ABCB1 and CES1 genotypes on the efficacy and safety of dabigatran: a systematic review and meta-analysis
Our study highlights the critical impact of pharmacogenetic variation on dabigatran exposure and bleeding risk. Key findings include:
– ABCB1 rs/148738 CT/TT genotypes → lower trough concentrations
– CES1 rs8192935 GG genotype → increased peak concentrations
– CES1 rs2244613 TT genotype → elevated peak/trough levels and bleeding risk
– CES1 rs2244613 GT genotype → increased trough levels only
These insights underscore the importance of personalized medicine in anticoagulant therapy and call for large-scale prospective studies across diverse populations to validate and expand upon our findings.
Grateful to our team and collaborators for their dedication and rigor. Let’s keep pushing the boundaries of precision pharmacotherapy!”
Title: The role of ABCB1 and CES1 genotypes on the efficacy and safety of dabigatran: a systematic review and meta-analysis
Authors: Weam Aldiban, Nada G. Hamam, Nereen A. Almosilhy, Kholoud Elsamman, Mohamed Wagdy, Doaa Mashaly, Suhel F. Batarseh, Youssef El-Sherif, Basma Badrawy Khalefa, Zina Otmani
Read full paper here.
Stay informed with Hemostasis Today.
-
Nov 3, 2025, 08:23The 1st Participant in A New CHECK-NIRS Clinical Study is Enrolled!
-
Nov 3, 2025, 08:15Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
-
Nov 3, 2025, 07:10Lisa Shea Shares Key Takeaways from NORD Summit 2025
-
Nov 3, 2025, 06:49Darshan Doshi on Results of iMODERN and ILIAS ANOCA Studies Presented at TCT 2025
-
Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
-
Nov 3, 2025, 04:56Nirupama Ramadas and Erica Sparkenbaugh on Thromboinflammation in SCD
-
Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
-
Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 3, 2025, 09:24Stephen Cornelissen: It’s Not Just About Emergencies — It’s About Everyday Care, Chronic Conditions and Hope
-
Nov 3, 2025, 06:57Maria Elisa Mancuso Reflects on 2025 Annual Congress of the Italian Association of Hemophilia Centres
-
Nov 3, 2025, 05:46Chandra Viswanathan: When Blood Safety Fails, We All Bleed - A Call for Reform and Responsibility
-
Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
-
Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry